|
Current Human Immune Therapy Center clinical trials for melanoma are listed below with a link to either our webpage or a National Cancer Institute webpage. The link will provide you with a description of the trial.
To view published papers related to our melanoma clinical trials, click here.
For more information about our melanoma trials,
contact Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Trials for Patients with Metastatic Disease
(unresected melanoma) |
Mel 46 trial (for patients with unresectable stage III or IV melanoma)
Evaluation of the Clinical Efficacy of Leukine® Administered in Conjunction with Paclitaxel in Patients with Advanced Melanoma
Click Mel 46 to print forms and learn more about the trial.
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Return to the top
E1602 trial (for patients with stage IV melanoma)
A Randomized Phase II Trial of Multi-Epitope Vaccination with Melanoma Peptides for Cytotoxic T-cells and Helper T-cells for Patients with Metastatic Melanoma
Click E1602 to print forms and learn more about the trial.
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Return to the top
Mel 47 trial (for patients with unresectable stage III or stage IV melanoma)
A Phase 2 Study of CCI-779 in Combination with Bevacizumab in Stage III or IV Melanoma
Click Mel 47 to print forms and learn more about the trial.
Click here for more information about this trial through the National Cancer Institute web site.
Contact: Melinh Jones, Phone: (434)243-9553, E-mail: mj9v@virginia.edu
Return to the top
BMS 004 trial
A Phase I Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination with Chemotherapy to Subjects with Advanced Solid Malignancies.
Principal Investigator: Amir Jazaeri, MD
For a summary of this trial click here.
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Return to the top
Trial Summaries
Mel 46 trial
Title: Evaluation of the Clinical Efficacy of Leukine® Administered in Conjunction with Paclitaxel in Patients with Advanced Melanoma
Principle Investigator: William Grosh, MD
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu
Trial Summary
The University of Virginia Health System's Cancer Center seeks adult participants with advanced melanoma for a research study.
If you decide to participate in this study, you will receive paclitaxel and GMCSF given in cycles of 21 days. Each cycle is one day of paclitaxel, 14 days of GMCSF, and 4 days of rest. Participants may receive up to 12 cycles of study drugs. Treatment will be at the UVA Cancer Center and some will be administered in your home. Your blood will be drawn and tested at the UVA GCRC.
There will be up to 23 visits in 9 months. Participants will then come in every 3 months for a total of 3 years. Each visit will last up to 3 hours.
Participant or participant's insurance will be responsible for the cost of required procedures. There will be no financial compensation for study completion.
Trial Calendar Click to view and print the calendar for this trial.
Screening Tests Click to view and print the screening tests for this trial.
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Return to the Top
E1602 trial
Title: A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma
Principal Investigator: Craig Slingluff, MD
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Trial Summary
The Human Immune Therapy Center of the Cancer Center at the University of Virginia Health System invites adults with melanoma to enroll in a research study.
The purpose of the study is to test investigational vaccines to see if they are safe to use in people with melanoma. Prior to, during, and after enrollment, physical examinations, blood tests, CT scans, skin and eye exams, and at week 4, sentinel node biopsy will be required. If enrolled, subjects will be randomly assigned to 1 of 4 groups. Each group will receive a vaccine with a differing formulation. The study involves 6 vaccine treatments over 7 weeks. If the results of these 6 treatments are favorable, participants become eligible to receive 18 booster vaccinations over an additional 2-year time period. All those enrolled will have blood drawn and physical exams during return visits to monitor general health and response to study vaccines. Participants will be followed for five years after the cessation of treatment to monitor for long-term side effects.
Participant or participant's insurance will be responsible for the cost of required procedures. There will be no financial compensation for study completion.
Consent Click to view and print the consent for this trial.
Screening Tests Click to view and print the screening tests for this trial.
E1602 diagram/schema Click to view and print a diagram from this trial.
Contact: Emily Stell, Phone:(434)982-6584, E-mail: ems2b@virginia.edu.
Return to the Top
Mel 47 trial
Title: A Phase 2 Study of CCI-779 in Combination with Bevacizumab in Stage III or IV Melanoma (Mel 47)
Principal Investigator: Craig Slingluff, MD
Contact: Johanna Loomba, Phone:(434)243-5946, E-mail: jloomba@virginia.edu.
Trial Summary
The Human Immune Therapy Center of the Cancer Center at The University of Virginia Health System seeks adults with melanoma for a research study.
The purpose of this study is to find out what effects drugs CCI-779 and bevacizumab have on participants with melanoma. CCI-779 is an experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration for use in melanoma or in any other cancer. Bevacizumab is also an experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration for use in melanoma.
Participants will undergo CT, MRI, and bone scans, physical examinations, biopsies, answer questions regarding medical history, have an EKG, and have urine and blood tests as part of this study. Participants will undergo as many as 26 cycles of treatment (each cycle lasts 14 days; thus, up to one year of treatment). Each cycle consists of infusions on days 1, 8, and may also include scans, physical exams, blood tests, and tumor and normal skin biopsies. Treatments will take place in the UVA Health System Cancer Center. Two overnight visits in the General Clinical Research Center at the UVA Health System are required. After completing study treatments, participants will have a 30-day follow-up visit with the doctor, and continue follow-up every three months for two years.
Participant or participant's insurance will be responsible for the cost of required procedures. There will be no financial compensation for study completion.
Consent form Click to view and print the consent form for this trial.
Contact: Melinh Jones, Phone: (434)243-9553, E-mail: mj9v@virginia.edu.
Return to the top
|
